echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Nat Commun: Phase Ib clinical results of inositol triphosphate treatment for patients with hepatobiliary tumors announced 

    Nat Commun: Phase Ib clinical results of inositol triphosphate treatment for patients with hepatobiliary tumors announced 

    • Last Update: 2021-08-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Existing studies have shown that hypoxia occurs in almost all solid tumors, and can lead to tumor invasion and metastasis, impaired immune response, and changes in tumor metabolism


    Immune blood vessel

    From the molecular level, hypoxia can lead to the stabilization of hypoxia-inducible factor (HIF), which is a key transcription factor that induces the expression of genes that respond to hypoxia


    The presence of


    So far, the treatment of tumor hypoxia has not been successful


    In preclinical models, ITPP can enhance the efficacy of subsequent chemotherapy by promoting the normalization of blood vessels


    Colorectal cancer

    The main goal of the study is to evaluate the safety and tolerability of the drug, and to determine the maximum tolerated dose.


     

    Radiological response after ITPP and chemotherapy

    ITPP and radiological response after chemotherapy ITPP and radiological response after chemotherapy

    The results showed that the maximum tolerated dose of ITPP is 12390 mg/m2 .


    The maximum tolerated dose of ITPP was 12390 mg/m2, 52% of patients had stable disease in morphology under single-agent ITPP treatment, and 60% of patients had stable disease


    Original source:

    Original source:

    Marcel A.


    Marcel A.


     

     



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.